Activity of anidulafungin in a murine model of candida krusei infection: Evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (l,3)-β-D-glucan levels

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1639-1641

  Ostrosky Zeichner, Luis ^a   Paetznick, Victor L ^a   Rodriguez, Jose ^a   Chen, Enuo ^a   Sheehan, Daniel J ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BETA 1,3 GLUCAN; FLUCONAZOLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; COLONY FORMING UNIT; CONTROLLED STUDY; IMMUNE DEFICIENCY; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL; TISSUE CULTURE;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BETA-GLUCANS; CANDIDA; CANDIDIASIS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; KIDNEY; MALE; MICE;

EID: 65649102666     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00955-08     Document Type: Article

References (21)

1. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M.27-A3. Clinical Laboratory Standards Institute, Wayne, PA.
2. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
3. Garey, K. W., R. S. Turpin, D. T. Bearden, M. P. Pai, and K. J. Suda. 2007. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int. J. Antimicrob. Agents 29:557-562. (Pubitemid 46560362)
4. Gumbo, T., G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50:3695-3700. (Pubitemid 44684883)
5. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-11524 (Pubitemid 43993195)
6. Kahn, J. N., G. Garcia-Effron, M.-J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878. (Pubitemid 46744179)
7. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024. (Pubitemid 38691592)
8. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Comely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527. (Pubitemid 46670281)
9. Marr, K. A. 2004. Invasive Candida infections: the changing epidemiology. Oncology 18:9-14.
10. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029. (Pubitemid 35461658)
11. Nucci, M., and K. A. Marr. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526. (Pubitemid 41099648)
12. Ostrosky-Zeichner, L., B. D. Alexander, D. H. Kett, J. Vazquez, P. G. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura, M. A. Finkelman, and J. H. Rex. 2005. Multicenter clinical evaluation of the (l-»3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659. (Pubitemid 41170353)
13. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, non-comparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661. (Pubitemid 41667052)
14. Ostrosky-Zeichner, L., V. L. Paetznick, J. Rodriguez, E. Chen, and D. J. Sheehan. 2007. Activity of anidulafungin (AFG) in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and serum beta-glucan (BG) levels, abstr. M-1840, p. 457. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
15. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893. (Pubitemid 47580382)
16. Perfect, J. R. 2004. Antifungal resistance: the clinical front. Oncology 18: 15-22.
17. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, E. Nagy, S. Dobiá-šova, M. Rinaldi, R. Barton, A. Veselov, and the Global Antifungal Surveillance Group. 2008. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:515-521.
18. Reboli, A. C, C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482. (Pubitemid 46919773)
19. Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.
20. Wiederhold, N. P., L. K. Njvar, R. Bocanegra, D. Molina, M. Olivo, and J. R. Graybill. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620. (Pubitemid 46744135)
21. Zaas, A. K., and B. D. Alexander. 2005. Echinocandins: role in antifungal therapy, 2005. Expert Opin. Pharmacother. 6:1657-1668. (Pubitemid 41167673)